Remove Dermatitis Remove Medical Remove Therapy
article thumbnail

New Ladder Helps Guide Choice of Non-steroidal Treatments in AD

The Dermatology Digest

A newly developed therapeutic ladder can help guide dermatologists and patients on the use of nonsteroidal treatment options for atopic dermatitis (AD). Ch’en, a medical student at the Albert Einstein College of Medicine in the Bronx, New York, and Peter A. The study appears in Dermatitis.

article thumbnail

Eczema (Atopic Dermatitis) vs. Psoriasis: Understanding the Differences

First Derm

Different Triggers and Causes : Eczema flare-ups can be triggered by allergens and irritants, whereas psoriasis can be exacerbated by stress, infections, and certain medications. Contact dermatitis from metals, latex, chemicals. Medications (lithium, beta-blockers, NSAIDs). 2] Why is Eczema Considered a Chronic Condition?

Eczema 59
article thumbnail

Atopic Dermatitis vs. Contact Dermatitis: What’s the Difference?

First Derm

Online Dermatologist Atopic Dermatitis vs. Contact Dermatitis: What’s the Difference? Atopic dermatitis (left) and contact dermatitis (right) display different symptoms. Contact Dermatitis : Triggered by external irritants or allergens, causing localized redness, blisters, and itching.

article thumbnail

Oh, The Places Dermatology Will Go in 2024!

The Dermatology Digest

In 2023, dermatologists and their patients welcomed new drugs for acne, psoriasis, alopecia areata, and more, and 2024 promises to deliver real-world data on these medications along with even more therapeutic innovations across the spectrum of cutaneous diseases. We will, for sure, have new medications for chronic urticaria.”

article thumbnail

Education Event: Bridging the Gap Between Medical Professionals + Estheticians 

Lipgloss and Aftershave

Third Annual Integrative Esthetics Conference for The Future of Skincare The third annual Integrative Esthetics Conference is a pioneering event by LearnSkin , that uniquely bridges medical professionals and estheticians, It will take place on September 29, 2024, in Arlington, Texas, and offers 7 educational topics.

article thumbnail

More Breaking News: U.S. FDA Approves Nemolizumab (Nemluvio, Galderma) for Patients with Moderate to Severe AD

The Dermatology Digest

Food and Drug Administration (FDA) has approved nemolizumab (Nemluvio, Galderma) for the treatment of patients aged 12 and older with moderate to severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies.

article thumbnail

Clinical Challenges in Treating Atopic Dermatitis

Dermatology Times

Panelists discuss how managing atopic dermatitis presents complex clinical challenges, including treatment resistance, medication adherence, identifying triggers, and tailoring therapies to individual patient needs and disease severity.